1,125 reports of this reaction
7.4% of all GLECAPREVIR AND PIBRENTASVIR reports
#3 most reported adverse reaction
NAUSEA is the #3 most commonly reported adverse reaction for GLECAPREVIR AND PIBRENTASVIR, manufactured by AbbVie Inc.. There are 1,125 FDA adverse event reports linking GLECAPREVIR AND PIBRENTASVIR to NAUSEA. This represents approximately 7.4% of all 15,159 adverse event reports for this drug.
Patients taking GLECAPREVIR AND PIBRENTASVIR who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is moderately reported among GLECAPREVIR AND PIBRENTASVIR users, representing a notable but not dominant share of adverse events.
In addition to nausea, the following adverse reactions have been reported for GLECAPREVIR AND PIBRENTASVIR:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 1,125 FDA reports for GLECAPREVIR AND PIBRENTASVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 7.4% of all adverse event reports for GLECAPREVIR AND PIBRENTASVIR, making it one of the most commonly reported side effect.
If you experience nausea while taking GLECAPREVIR AND PIBRENTASVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.